Felzartamab Drug Asset Due Diligence Report 2026

This Felzartamab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Late-stage development and multiple transactions support continued diligence, with renal endpoint execution and immune-safety monitoring as key gates.

The central underwriting question is whether Felzartamab can convert its Monoclonal antibody profile and CD38 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Felzartamab (query alias: felzartamab)
Modality / target	Monoclonal antibody; CD38; CD38 inhibitors, ADCC, Antibody-dependent cellular phagocytosis (ADCP) effects
Highest global status	NDA/BLA
Originator	MorphoSys AG
Active developers	TJ Biopharma Hangzhou Co Ltd, Human Immunology Biosciences, Inc., Biogen, Inc.

The MCP disease footprint includes Multiple Myeloma, Microvascular Disease, Idiopathic Membranous Glomerulonephritis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06935357	Phase 3	Recruiting	454	Percent Change From Baseline in Proteinuria as Measured by the Urine Protein: Creatinine Ratio (UPCR)
NCT07444489	Phase 3	Enrolling by invitation	201	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI)
NCT06962800	Phase 3	Recruiting	180	Percentage of Participants who Achieve Complete Remission (CR) at Week 104

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy

Phase 2; n=54; evaluation: not stated. Reported fields: Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9(Least Squares Mean): Geometric LS Mean Ratio = 1.11(95% CI, 0.67 - 1.84), P-Value = 0.6837; Geometric LS Mean Ratio = 0.92(95% CI, 0.54 - 1.57), P-Value = 0.7599; Geometric LS Mean Ratio = 0.82(95% CI, 0.49 - 1.35), P-Value = 0.4165; Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9(Least Squares Mean) = -30.6 gram per gram (g/g) (Standard Error, 21.72); Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9(Least Squares Mean): Geometric LS Mean Ratio = 1.11(95% CI, 0.67 - 1.84), P-Value = 0.6837; Geometric LS Mean Ratio = 0.92(95% CI, 0.54 - 1.57), P-Value = 0.7599; Geometric LS Mean Ratio = 0.82(95% CI, 0.49 - 1.35), P-Value = 0.4165

Preservation of Humoral Immunity and Response to Vaccination and Infection in Felzartamab-Treated Patients with IgAN: Data from the Phase 2 IGNAZ Study

Phase 2; n=54; evaluation: Positive. Reported fields: Anti-SARS-CoV-2(positive) = 45.0 Pts

Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy

Phase 2; n=54; evaluation: Positive. Reported fields: AE = Felzartamab safety was consistent with prior observations; adverse events were predominantly grade 1 or 2. ; AE = Felzartamab safety was consistent with prior observations; adverse events were predominantly grade 1 or 2. ; AE = Felzartamab safety was consistent with prior observations; adverse events were predominantly grade 1 or 2.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Felzartamab addresses Multiple Myeloma, Microvascular Disease, Idiopathic Membranous Glomerulonephritis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 8 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-04-20	Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region	NDA/BLA	US$100.0M upfront; US$750.0M milestones; US$850.0M stated total
2025-04-08	天境生物与渤健就CD38单抗达成临床研究合作！	NDA/BLA	Financial terms not disclosed
2024-05-22	Biogen, Inc. acquires Human Immunology Biosciences, Inc.	Phase 2	US$1,150.0M upfront; US$650.0M milestones; US$1,800.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for reducing Anti-CD38 MAB drug interference in serological assays”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Infection, immunoglobulin depletion, and vaccination response
Renal indication-specific endpoint and biopsy variability
Territorial rights and lifecycle-management complexity

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO